Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05643118 · ClinicalTrials.gov registry record · Phase 1

Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

A Phase 1 study of Neovascular Age-related Macular Degeneration, sponsored by Olix Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
21
Enrollment target
5
Study locations

NCT05643118 is a Phase 1 study of Neovascular Age-related Macular Degeneration that has completed, run by Olix Pharmaceuticals. The registered enrollment target is 21 participants, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05643118, a Phase 1 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Olix Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
21 participants
Enrollment target
5
Study locations

Study Summary

This is a Phase 1, multicenter, open-label, single- and multi-dose, dose-escalating study of OLX10212 in patients with neovascular age-related macular degeneration (AMD). This study is composed of 2 parts: Part A and Part B. Part A is a single ascending dose study, and Part B is a multiple ascending dose study. The primary objective is to evaluate the safety and tolerability of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD. The exploratory objectives are to evaluate the preliminary efficacy of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD, and to evaluate the pharmacokinetics (PK) of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD.

Conditions Studied

Neovascular Age-related Macular Degeneration

Interventions

  • GENETIC OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)

Study Locations (5)

California

  • California Retina Consultants - Santa Maria

Illinois

  • University Retina - Oak Forest

Missouri

  • The Retina Institute - St Louis

New York

  • Ophthalmic Consultants of the Capital Region - Troy

Texas

  • Texas Retina Consultants - Bellaire

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2023-01-04
Est. Completion 2025-11-10
Phase Phase 1

Sponsor

Olix Pharmaceuticals

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05643118

The ClinicalTrials.gov registry entry for NCT05643118 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (95% lower). The listed sponsor is Olix Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA) is the first listed.

NCT05643118 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Missouri.

Frequently Asked Questions

What is clinical trial NCT05643118 about?

NCT05643118 is a clinical study titled "Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration". This is a Phase 1, multicenter, open-label, single- and multi-dose, dose-escalating study of OLX10212 in patients with neovascular age-related macular degeneration (AMD). This study is composed of 2 parts: Part A and Part B. Part A is a single ascending dose study, and Part B is a multiple ascending...

What is the current status of trial NCT05643118?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-01-04. Estimated completion is 2025-11-10.

What conditions does trial NCT05643118 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.

What interventions are being tested in trial NCT05643118?

The interventions under investigation include: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA) (GENETIC).

Who is sponsoring clinical trial NCT05643118?

This trial is sponsored by Olix Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05643118 being conducted?

This trial has 5 study locations across California, Illinois, Missouri, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neovascular Age-related Macular Degeneration

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.